Case Describes Delay in Immune Response With COVID-19 Vaccine, Tdap Coadministration
The case involved a 29-year-old female patient who was administered the Tdap vaccine 1 day after receiving the first dose of the BNT162b2 vaccine.
All articles by Diana Ernst, RPh
Aduhelm Gets Accelerated Approval for Alzheimer Disease
The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
Moderna COVID-19 Vaccine Safe, Effective in Adolescents
The TeenCOVE study (ClinicalTrials.gov: NCT04649151) included over 3700 US adolescents aged 12 to less than 18 years.
FDA Cracks Down on Companies Selling Unapproved CBD Products
The products described in the warning letters are being marketed as topical pain therapies, though none have actually been evaluated by the FDA.
FDA Committees Vote on Novel Therapy for Schizophrenia, Bipolar I Disorder
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Aducanumab Gets Priority Review for Alzheimer Disease
The FDA has accepted for Priority Review the Biologics License Application for aducanumab (Biogen) for the treatment of Alzheimer disease.
Benefits Seen With Deutetrabenazine in Tardive Dyskinesia Regardless of Age
Treatment with deutetrabenazine was found to be beneficial for both younger (<55 years) and older (≥55 years) patients with tardive dyskinesia, according to findings from a recently published post hoc analysis.
FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
FDA Bans Electrical Stimulation Devices for Self-Injurious, Aggressive Behavior
The use of electrical stimulation devices (ESDs) to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration (FDA).
Troriluzole No Better Than Placebo in Generalized Anxiety Disorder Study
Results showed a mean change from baseline of -9.28 points (95% CI, -10.23 to -8.32) on the HAM-A total score in patients treated with troriluzole compared with -9.35 points (95% CI, -10.34 to -8.36) with placebo (P =.917).
- Loading...
Loading...
Loading... 
Loading...